ID18143A - Penghambat metaloprotease amina siklik tersubstitusi - Google Patents

Penghambat metaloprotease amina siklik tersubstitusi

Info

Publication number
ID18143A
ID18143A IDP972994A ID972994A ID18143A ID 18143 A ID18143 A ID 18143A ID P972994 A IDP972994 A ID P972994A ID 972994 A ID972994 A ID 972994A ID 18143 A ID18143 A ID 18143A
Authority
ID
Indonesia
Prior art keywords
metaloprotease
amina
resistant
substituted cycle
compounds
Prior art date
Application number
IDP972994A
Other languages
English (en)
Indonesian (id)
Inventor
Michael George Natchus
Stanislaw Pikul
Roger Gunnard Bookland
Biswanath De
Neil Gregory Almstead
Menyan Cheng
Yetunde Olabisi Taiwo
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID18143A publication Critical patent/ID18143A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Confectionery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
IDP972994A 1996-08-28 1997-08-28 Penghambat metaloprotease amina siklik tersubstitusi ID18143A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2484296P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
ID18143A true ID18143A (id) 1998-03-05

Family

ID=21822685

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972994A ID18143A (id) 1996-08-28 1997-08-28 Penghambat metaloprotease amina siklik tersubstitusi

Country Status (29)

Country Link
US (6) US6417219B1 (cs)
EP (1) EP0927161B1 (cs)
JP (2) JP3541043B2 (cs)
KR (1) KR100323272B1 (cs)
CN (1) CN1232451A (cs)
AT (1) ATE226193T1 (cs)
AU (1) AU741893B2 (cs)
BR (1) BR9713465A (cs)
CA (1) CA2263928A1 (cs)
CO (1) CO4900036A1 (cs)
CZ (1) CZ63199A3 (cs)
DE (1) DE69716449T2 (cs)
DK (1) DK0927161T3 (cs)
ES (1) ES2201318T3 (cs)
HU (1) HUP0000478A3 (cs)
ID (1) ID18143A (cs)
IL (1) IL128666A (cs)
MY (1) MY116959A (cs)
NO (1) NO315371B1 (cs)
NZ (1) NZ334256A (cs)
PE (1) PE109098A1 (cs)
PL (1) PL331802A1 (cs)
PT (1) PT927161E (cs)
RU (1) RU2221782C2 (cs)
SK (1) SK25099A3 (cs)
TR (1) TR199900431T2 (cs)
TW (1) TWI232218B (cs)
WO (1) WO1998008815A1 (cs)
ZA (1) ZA977698B (cs)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195034T3 (es) * 1995-12-08 2003-12-01 Agouron Pharma Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
DK0927161T3 (da) * 1996-08-28 2003-02-17 Procter & Gamble Substitueret cyklisk amin-metalloproteaseinhibitorer
US6872742B2 (en) * 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
TR199901926T2 (xx) 1997-02-11 1999-12-21 Pfizer Inc. Arils�lfonil hidroksamik asit t�revleri
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
RU2208609C2 (ru) 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058531A1 (en) * 1998-05-14 1999-11-18 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
EP1117372A2 (en) * 1998-09-30 2001-07-25 The Procter & Gamble Company Method of treating hair loss using sulfonamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
TR200102523T2 (tr) 1999-03-03 2002-02-21 The Procter & Gamble Company Alkenil ve alkinil içeren metaloproteaz inhibitörleri
PL350452A1 (en) 1999-03-03 2002-12-16 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
AU3196100A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2001010838A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent compounds
AU6388500A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent sulfonamides
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
KR100372757B1 (ko) * 2000-04-07 2003-02-17 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
DE60134854D1 (de) 2000-06-30 2008-08-28 Procter & Gamble Orale zubereitungen, die wirtsantwortmodulierenden wirkstoffe enthalten
WO2002006222A1 (en) * 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
CN100406439C (zh) * 2000-07-19 2008-07-30 霍夫曼-拉罗奇有限公司 作为金属蛋白酶抑制剂的吡咯烷衍生物
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
US7176217B2 (en) 2001-11-13 2007-02-13 Shiseido Co., Ltd. Azabicyclo compound matrix metalloprotease inhibitor and skin preparation
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20040258769A1 (en) * 2003-06-20 2004-12-23 Barker Ronnie C. Use of ocular vitamins in conjunction with other treatment methods for AMD
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
WO2006036024A1 (ja) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited プロトンポンプ阻害薬
WO2006120574A2 (en) * 2005-02-18 2006-11-16 Innodia Inc. Analogs of 4-hydroxyisoleucine and uses thereof
GEP20105044B (en) 2005-08-30 2010-07-12 Takeda Pharmaceuticals Co 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
PL1966130T3 (pl) 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
KR101629181B1 (ko) 2008-08-27 2016-06-13 다케다 야쿠힌 고교 가부시키가이샤 피롤 화합물
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
WO2013050476A1 (en) * 2011-10-04 2013-04-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) New apoptosis inducing compounds
EP3515889A1 (en) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
CA3036933A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954158A (en) * 1983-08-16 1990-09-04 University Of Georgia Research Foundation, Inc. 2,3-methanoproline
ZA877471B (en) * 1986-10-08 1988-04-05 Bristol-Myers Company 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
DE69519751T2 (de) * 1995-04-20 2001-04-19 Pfizer Inc., New York Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5795890A (en) * 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
ES2195034T3 (es) * 1995-12-08 2003-12-01 Agouron Pharma Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
DK0927161T3 (da) * 1996-08-28 2003-02-17 Procter & Gamble Substitueret cyklisk amin-metalloproteaseinhibitorer
US6376506B1 (en) * 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6261775B1 (en) * 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Also Published As

Publication number Publication date
US6858628B2 (en) 2005-02-22
ATE226193T1 (de) 2002-11-15
CA2263928A1 (en) 1998-03-05
HK1020962A1 (en) 2000-05-26
ES2201318T3 (es) 2004-03-16
NO315371B1 (no) 2003-08-25
KR100323272B1 (ko) 2002-02-06
CN1232451A (zh) 1999-10-20
CO4900036A1 (es) 2000-03-27
BR9713465A (pt) 2000-03-28
NZ334256A (en) 2000-11-24
US20050101567A1 (en) 2005-05-12
AU4074197A (en) 1998-03-19
RU2221782C2 (ru) 2004-01-20
US20020072517A1 (en) 2002-06-13
IL128666A (en) 2005-09-25
US20020061877A1 (en) 2002-05-23
PL331802A1 (en) 1999-08-02
KR20000035922A (ko) 2000-06-26
SK25099A3 (en) 2000-02-14
DE69716449T2 (de) 2003-08-07
NO990855D0 (no) 1999-02-23
US6569855B2 (en) 2003-05-27
NO990855L (no) 1999-04-23
MY116959A (en) 2004-04-30
US20050154019A1 (en) 2005-07-14
EP0927161B1 (en) 2002-10-16
HUP0000478A3 (en) 2000-10-30
JP2000516955A (ja) 2000-12-19
JP2004115531A (ja) 2004-04-15
US6417219B1 (en) 2002-07-09
PE109098A1 (es) 1999-02-19
TWI232218B (en) 2005-05-11
DK0927161T3 (da) 2003-02-17
US20030191163A1 (en) 2003-10-09
DE69716449D1 (de) 2002-11-21
WO1998008815A1 (en) 1998-03-05
HUP0000478A2 (hu) 2000-09-28
CZ63199A3 (cs) 1999-08-11
EP0927161A1 (en) 1999-07-07
JP3541043B2 (ja) 2004-07-07
TR199900431T2 (xx) 1999-04-21
PT927161E (pt) 2003-12-31
AU741893B2 (en) 2001-12-13
IL128666A0 (en) 2000-01-31
ZA977698B (en) 1998-02-23

Similar Documents

Publication Publication Date Title
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
PT966465E (pt) Inibidores do enzima imfdh
CA2264254A1 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
EA200100867A1 (ru) Сульфаматогидроксамовая кислота как ингибитор металлопротеаз
EA200100992A1 (ru) Ингибиторы фермента impdh
DK1140918T3 (da) Thrombininhibitorer
NO983688L (no) Serin-protease-inhibitorer
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
HK1044754A1 (zh) 含有烯烃基-和烯烃金属蛋白酶抑制剂
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
DE60329326D1 (de) Tace inhibitoren
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
TR200003065T2 (tr) Nöraminidazların inhibitörleri olarak pirolidinler.
WO2001070693A3 (en) Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0109354A (pt) Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
MX9704968A (es) Inhibidores que contienen acido hidroxamico de metaloproteasas de matriz.
GEP20032923B (en) Sulphonamide Derivatives as Prodrugs of Aspartyl Protease Inhibitors, Pharmaceutical compositions containing the Same and Methods for Treatment
GEP20022764B (en) HIV Protease Inhibitors, Pharmaceutical Compositions and Methods for Inhibiting HIV Protease